Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801)

Gynecologic Oncology

Volumn 126, Issue 1, 2012, Pages 36-40

  Tang, Amy ^a   Kondalsamy Chennakesavan, Srinivas ^b   Ngan, Hextan ^c   Zusterzeel, Petra ^d   Quinn, Michael ^e   Carter, Jonathan ^f   Leung, Yee ^g   Obermair, Andreas ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QUEEN MARY HOSPITAL   (Hong Kong)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ROYAL WOMEN'S HOSPITAL   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

CA125; Ovarian tumors of low malignant potential; Survival

Indexed keywords

CA 125 ANTIGEN;

ADULT; ARTICLE; CANCER CENTER; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FEMALE FERTILITY; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HYSTERECTOMY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RADICAL HYSTERECTOMY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; TREATMENT FAILURE;

CA-125 ANTIGEN; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84862768379     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.02.031     Document Type: Article

References (20)

1. Cadron I, Amant F, Van Gorp T, Neven P, Leunen K, Vergote I. The management of borderline tumours of the ovary. Curr Opin Oncol 2006;18:488-93. (Pubitemid 44199846)
2. Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol 2006;103:841-7. (Pubitemid 44830065)
3. Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 2002;86:34-7. (Pubitemid 34757048)
4. Boran N, Cil AP, Tulunay G, Ozturkoglu E, Koc S, Bulbul D, et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 2005;97:845-51. (Pubitemid 40824656)
5. Morice P, Camatte S, Rey A, Atallah D, Lhomme C, Pautier P, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 2003;14:592-8. (Pubitemid 41295089)
6. Wu TI, Lee CL,WuMY, Hsueh S, Huang KG, Yeh CJ, et al. Prognostic factors predicting recurrence in borderline ovarian tumors. Gynecol Oncol 2009;114:237-41.
7. Fauvet R, Boccara J, Dufournet C, David-Montefiore E, Poncelet C, Darai E. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer 2004;100:1145-51. (Pubitemid 38325941)
8. Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO. Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol 2004;104:261-6. (Pubitemid 40458870)
9. Chan JK, Lin YG, Loizzi V, Ghobriel M, DiSaia PJ, Berman ML. Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. J Reprod Med 2003;48:756-60. (Pubitemid 37314940)
10. Camatte S, Morice P, Pautier P, Atallah D, Duvillard P, Castaigne D. Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. BJOG 2002;109:376-80. (Pubitemid 37338013)
11. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545-51. (Pubitemid 26134212)
12. Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D, et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol 2005;23:5938-42.
13. Chan J. The pattern of CA-125 normalization during chemotherapy predicts for recurrence-free and overall survival in patients with high-risk early-stage ovarian cancer: a gynecologic oncology group study; SGO abstract 36. Annual scientific meeting of the Society of Gynecologic Oncologists. San Francisco; 2010.
14. Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. CA 125 in gynecological pathology-a review. Eur J Obstet Gynecol Reprod Biol 1993;49:115-24.
15. Kolwijck E, Thomas CM, Bulten J, Massuger LF. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature. Int J Gynecol Cancer 2009;19:1335-8.
16. Rice LW, Lage JM, Berkowitz RS, Goodman A, Muto MG, Knapp RC, et al. Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol 1992;46:226-9.
17. Tamakoshi K, Kikkawa F, Shibata K, Tomoda K, Obata NH, Wakahara F, et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol 1996;62:67-72. (Pubitemid 26234547)
18. Lenhard MS, Nehring S, Nagel D, Mayr D, Kirschenhofer A, Hertlein L, et al. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors. Clin Chem Lab Med 2009;47:537-42.
19. Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, et al. Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol 2011;120:480-4.
20. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44. (Pubitemid 30422619)